Imara announces primary endpoint change in the ardent phase 2b clinical trial of tovinontrine (imr-687) in sickle cell disease

Primary endpoint to be changed to annualized rate of vocs following written u.s. food and drug administration recommendation
ELVN Ratings Summary
ELVN Quant Ranking